PRKDC and lung cancer: Combined rapamycin and DNA-PK inhibitor treatment was required to suppress AKT phosphorylation and also decreased 4EBP1 phosphorylation in human lung cancer models (89), supporting that DNA-PK is involved in regulating mTOR signaling.